Save The Date: November 1-2, 2017
10 on the Park, New York City

2015 Emerging Company Showcase

Innovative, Fundable, Early Stage Opportunities

Each company featured in the Emerging Company Showcase was nominated, reviewed and invited to present based upon their innovative science and the quality of their management team. They presented before a panel of ‘Pitch Doctors’, early stage VCs and investors, corporate VCs, strategic partners and other investors and advisors, who asked questions about their science and strategy.

2015 Presenting Companies

alitair

Alitair Pharmaceuticals, Inc., Morristown NJ: A specialty pharmaceutical company with a focus on the respiratory space, currently developing two Orphan drugs for bronchiectasis.

aridis_web2

Aridis Pharmaceuticals, San Jose, CA: Developing a suite of anti-infective monocolonal antibodies using a discovery platform technology to target infectious diseases including nosocomial and ventilator-associated Pneumonia, MRSA, and Pseudomonas aeruginosa infections that affect Cystic Fibrosis patients.

BMSEED_web2

BMSEED, LLC, Tempe, AZ: Developed a monitoring device for traumatic brain injury that utilizes a stretchable gold film that monitors electrophysiological activity in cells and tissue.

cellsource_web2

Cell Source, Inc.,New York, NY: Utilizing breakthrough immune tolerance and organ regeneration technologies to revolutionize transplantation, cancer treatment and reversal of vital organ disease.

cenna_web2

Cenna Biosciences, San Diego, CA: Developing a novel disease-modifying small peptide to block amyloid production in Alzheimer’s Disease.

cloud_web2

Cloud Pharmaceuticals, Research Triangle Park, NC: Uses the power of cloud computing, quantum mechanics, and molecular property simulation to inform and improve rational drug discovery and design.

codagenix_web2

Codagenix Inc., Stony Brook, NY: Developing live attenuated vaccines using unique algorithm to restructure viral genomes, resulting in highly attenuated vaccine strains that are therapeutically effective at doses much smaller than current therapies.

DepYmed_web1

DepyYmed, Cold Spring Harbor, NY: Has developed Trodusquemine – a highly selective inhibitor of the critical protein tyrosine phosphatase 1B (PTP1B) enzyme with applications in oncology, diabetes, and obesity and is currently being developed as a therapy for HER2-positive breast cancer.

efferent_web3

Efferent Labs, Buffalo, NY: Developing implantable biosensors utilizing living cells to assess cellular function in vivo which has multiple applications including preclinical R&D, clinical testing, oncology, cardiology, and metabolic diseases.

envisagenics_web3

Envisagenics, Cold Spring Harbor, NY: Developing a cloud-based software platform for the analysis of splicing, translating NextGen sequencing data into BioPharma R&D intelligence through a SaaS business model.

epigen_web2

Epigen Biosciences, Inc., San Diego, CA: Utilizing advanced lead optimization methods including computational design, scaffold-hopping, focused library synthesis and screening to discover novel assets for unmet medical needs with a focus on new treatments for pain.

Escend_web2

Escend Pharmaceuticals, Inc., Menlo Park, CA: Developing small molecule therapeutics for cancer orphan indications, including therapeutics that kill cancer stem cells in chronic myelogenous leukemia and related hematologic malignancies.

genesegues_web2

GeneSegues Therapeutics, Minnetonka, MN: developing next generation of targeted drugs for cancer treatment that combines innovative RNAi therapeutics with novel sub-50 nanometer capsule technology that increases the amount of RNAi drug delivered to both primary and metastatic tumors.

genomicexpression_web3

Genomic Expression, New York, NY: Developing sequence-based cancer diagnostics using RNA markers to predict chemo, immune, and targeted therapy responsiveness.

gismo_web3

Gismo Therapeutics, Inc., Lexington, KY: Developing first-in-class therapeutics for neurodegenerative diseases using Glycosaminoglycan-Interacting Small Molecules (GISMO) platform technology to target GAG-amyloid complexes involved in Alzheimer’s and Parkinson’s diseases.

g3_web2

Global Genomics Group, Atlanta, GA: Leveraging molecular profiles of human health, precision phenotyping, integrated omics, and advanced analytics to develop life changing diagnostics and therapeutics.

irr_web

Inflammatory Response Research Inc., Santa Barbara, CA: Developing therapeutics for the treatment of inflammatory disorders and conditions including influenza, common cold, and traumatic brain injury.

innovimmune_web3

Innovimmune, Brooklyn, NY: Developing oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune and ImmunoInflammatory Diseases.

intrommune_web2

Intrommune Therapeutics, New York, NY: Developing a revolutionary new treatment platform for food allergies that is safe, effective and convenient. Intrommune’s first product is a therapy for patients who suffer fro​m peanut allergy.

kendo_web2

Kenkodo, Potsdam, Germany: Developing a cloud based, personal digital health monitor that measures metabolic changes in blood samples and by tracking lifestyle information submitted via the Kenkodo smartphone application.

linus_web3

Linus Oncology, Miami, FL: Developing a phase II ready first-in-class indenoisoquinoline anti-cancer therapeutics as successor agents to the Topoisomerase I inhibitor Camptothecin.
memgen_web2

Memgen, Houston, TX: Clinical-stage biotech company. Our ISF35 cancer immunotherapy with checkpoint inhibitors cures 40% of mice with B16 melanoma tumor. Phase I/II clinical trial of ISF35 and Keytruda in refractory metastatic melanoma starting February 2016 at MD Anderson Cancer Center.

NeuroGenetic_web2

NeuroGenetic Pharmaceuticals, Del Mar, CA: Developing a novel approach to the treatment and prevention of Alzheimer’s disease by modulating the activity of the key enzymes involved in the production of Amyloid beta 42, a primary component of amyloid plaques.

NeuroOpLogo1_web1

NeurOp, Inc., Atlanta, GA: Small molecule drug discovery company targeting various subunits of N-methyl-D-aspartate (NMDA) receptors for the treatment and prevention of CNS disorders including stroke (cerebral ischemia), Alzheimer’s, Parkinson’s, schizophrenia, depression, and neuropathic pain.

pathmaker_web2

PathMaker Neurosystems, Inc., Boston, MA: Commercializing breakthrough advances in non-invasive Trans-Spinal Direct Current Stimulation (tsDCS) for the treatment of patients with neuromotor disorders including paralysis, muscle weakness and muscle tone disorders.
phdbiosciences_web3

PHD Biosciences, New York, NY: Developing small molecule targeted enzyme inhibitors for oncology and sickle cell disease that operate by unique mechanisms of action from all known therapeutics.

phoenixnest_web3

Phoenix Nest, Inc., Brooklyn, NY: Developing treatments for Sanfilippo Syndrome IIIC and IIID, using approaches that include enzyme replacement and chaperone therapies.

pixar_web3

PixarBio, Medford, MA: Developing a novel drug delivery platform to achieve sustained release of non-opiate drugs to treat post-operative, acute and chronic pain.

renovo_web2

Renovo Neural, Inc., Cleveland, Ohio: Using a highly innovative screening technology to identify novel small molecules that stimulate neural remyelination for the treatment of multiple sclerosis.

regenix_web1

Rgenix, New York, NY: Designing first-in-class oncology therapeutics using discovery platform to identify and validate novel post-transcriptionally regulated targets.

riparian_web1

Riparian Pharma, Cambridge, MA: Developing small molecule activators of vasoprotective pathways that have the potential to treat a wide range of inflammatory diseases including atherosclerosis, cardiovascular disease, cirrhosis and organ transplantation.

Savara_web2

Savara Pharmaceuticals, Austin, TX: Developing small molecule inhalation therapeutic for treatment of MRSA infections in cystic fibrosis and chronic care patients.

siamab_web2

Siamab Therapeutics, Newton, MA: Developing novel cancer immunotherapies. Siamab has developed a platform of technologies that enable the rapid discovery and development of therapeutic antibodies that bind to a novel class of carbohydrate antigens present on cancer cells.

susavion_web2

Susavion Biosciences Inc., Tempe, AZ: A cancer immunotherapy company dedicated to the design of novel peptides for the treatment of cancer and viral infections.

symbiotichealth_web1

Symbiotic Health, New York, NY: Developing a treatment for C. difficile infections using a novel targeted delivery method of therapeutic bacteria in stable oral capsules to restore the microbiome of the gastrointestinal tract.

synvivo_web2

SynVivo, Houston, TX: Developing a proprietary microfluidic chip platform technology for use in oncology, neurology and inflammation studies that simulates the circulation inside any tissue with respect to flow, shear, and pressure.

synzyme_new3

SynZyme Technologies LLC, Sioux Falls, SD: Developing therapeutic agents for the treatment of hypoxia and impaired blood flow using their platform superoxide dismutase mimetic nanoparticles to control vascular superoxide. This platform has demonstrated efficacy in preclinical models of stroke, in traumatic brain injury accompanied by hemorrhagic shock, and in sickle cell disease. Additional indications include use in pre-hospital emergency care and in cancer therapy.

Targagenix_web1

TargaGenix, Inc. Stony Brook, NY: Developing a novel therapy effective against taxane-resistant tumors by targeting cancer stem cells and bulk tumor cells.

theragnostic_web3

Theragnostic Technologies, Stony Brook, NY: Focusing on research and development of high performance multifunctional nanotechnology-enabled materials and devices.

traverse_web3

Traverse Biosciences, Stony Brook, NY: Commercializing novel drug candidates for the treatment of inflammatory diseases and related conditions affecting humans and companion animals.

vala_web2

Vala Sciences, San Diego, CA: Developing a miniaturized, cell-based optogenetic multiparametric assay for high-throughput cardiotoxicity testing in an automated platform.

zoetic2_web3

Zoetic Pharmaceuticals, Buffalo, NY: Developing a nanoparticle-based platform technology to enhance the safety and efficacy of biotherapeutics by reducing immunogenicity and extending the half-life of IV injected biotherapeutics.

Note about the presenting companies:

Companies selected to present at the Life Sciences Summit have raised $20 million or less with pre-clinical to Phase 2A assets.

2015 Participating Strategic Partners and Investors:

A. M. Pappas & Associates
Accelerate Long Island
Accelerator Corporation
Acorda Therapeutics
Aisling Capital LLC
Alexion
Apple Tree Partners
AstraZeneca
Astute Capital Management
BioAdvance Ventures
COI Pharmaceuticals
Dabar Investment Associates
E Squared Capital Management
Easton Capital
Eisai, Inc.
Eli Lilly
Ellington Healthcare Asset Management
Flagship Ventures
F-Prime Capital Partners
FundRx, Inc
HBS Alumni Angels New York
Health Investment & Financing Corporation
Hercules Technology Growth Capital
Horizon Technology Finance
J&J
Kadmon
KEMA Partners
Landmark Angels
Livingston Securities
MedImmune
Medora Fund
MEDPRO Investors
Merck
MRL Ventures
Pappas Ventures
Park Avenue Capital Mgmt Intl
Pfizer
Polaris Venture Partners
Regeneron
Remiges Ventures
Roche
SternAegis Ventures
Takeda
Technological & Investment Horizons
Temasek Bioscience Partners
Thomas, McNerney & Partners
Trillium Medical Ventures
World Tech Ventures